Home
Focus & approach
Dare
Build
Criteria
Portfolio
Team & Partners
Team Investment Management
Advisory board
Partners
vacancies
News & Events
News
Media
Events
Impact & ESG
Impact & ESG
impact Committee
Contact
Home
Focus & approach
Dare
Build
Criteria
Portfolio
Team & Partners
Team Investment Management
Advisory board
Partners
vacancies
News & Events
News
Media
Events
Impact & ESG
Impact & ESG
impact Committee
Contact
news
News and Events
News
Media
Events
Featured
Oct 25, 2024
Meet Eline van Beest, Operational Partner at Thuja
Oct 25, 2024
Oct 25, 2024
Oct 14, 2024
Thuja's 2023 Impact & ESG Annual Report
Oct 14, 2024
Oct 14, 2024
Sep 11, 2024
Synerkine Pharma receives European Orphan Drug Designation for SK-01 to treat Complex Regional Pain Syndrome
Sep 11, 2024
Sep 11, 2024
Jun 12, 2024
We are delighted to share that Thuja led the extension of Tacalyx’s seed financing!
Jun 12, 2024
Jun 12, 2024
Apr 11, 2024
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
Apr 11, 2024
Apr 11, 2024
Apr 4, 2024
Meet Tyler Hayes, Principal at Thuja
Apr 4, 2024
Apr 4, 2024
Feb 7, 2024
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine
Feb 7, 2024
Feb 7, 2024
Jan 8, 2024
Thuja promotes Eleanor Price to Associate
Jan 8, 2024
Jan 8, 2024
Nov 9, 2023
Meet Aartie Nanda, office & communication manager at Thuja
Nov 9, 2023
Nov 9, 2023
Nov 2, 2023
Thuja Capital co-leads a €12M Seed investment in Artica Therapeutics.
Nov 2, 2023
Nov 2, 2023
News archive
